Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 78 citations in OpenAlex.

1. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.Arthritis research & therapy · 2019
   Trial
2. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial.Trials · 2015
   Trial
3. Effect of dose tapering policy on the prescription of advanced therapy for rheumatoid arthritis: a retrospective analysis of clinical and cost outcomes in Taiwan.Journal of comparative effectiveness research · 2026
   Article
4. Dose Tapering of Advanced Therapies in Psoriatic Arthritis: Clinical Predictors and Outcomes in a Biosimilar-Dominant Real-Life Cohort.Journal of clinical medicine · 2025
   Article
5. The Saudi consensus recommendations for the management of psoriatic arthritis (2023).Clinical rheumatology · 2024
   Review
6. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.Arthritis research & therapy · 2023
   Observational
7. Hospital crowdedness evaluation and in-hospital resource allocation based on image recognition technology.Scientific reports · 2023
   Article
8. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.European journal of clinical pharmacology · 2020
   Article
9. Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2019
   Article
10. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study.Arthritis research & therapy · 2019
    Observational
11. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting.Frontiers in pharmacology · 2019
    Article
12. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.Drugs · 2018
    Review
13. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.British journal of clinical pharmacology · 2018
    Article
14. REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.Heliyon · 2017
    Article
15. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.Rheumatology international · 2017
    Article
16. Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?British journal of clinical pharmacology · 2017
    Review
17. Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.ClinicoEconomics and outcomes research : CEOR · 2017
    Article
18. Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.Rheumatology international · 2016
    Article
19. Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis.PloS one · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

19 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as